Tumor-Selective Adenovirus E1a/E1b Mutants With Pea3 Site Deletions
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oncolytic viruses, such as ONYX-015, lack sufficient potency and tumor-selective control over viral protein expression, leading to non-selective expression in both normal and tumor cells, which limits their therapeutic efficacy.
Innovation Solution
Engineering recombinant adenoviruses with modified E1a regulatory sequences, specifically deleting Pea3 binding sites and retaining E2F binding sites, to achieve tumor-selective expression of E1a isoforms and insert transgenes like TNF at the E1b-19K site, thereby enhancing tumor-specific replication and cytotoxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ONYX-015 is used with deletion of E1b-55k gene to achieve tumor-selective replication, then replication is permitted in tumors with p53 defects, but viral replication efficiency is reduced due to loss of mRNA transport function
Solution Approach 1:
The patent modifies the regulatory parameters of the E1a gene by deleting specific Pea3 binding sites (Pea3 II and Pea3 III) from the E1a promoter region. This parameter change in the regulatory sequence alters the expression pattern of E1a, achieving tumor-selective replication while compensating for the lost mRNA transport function through enhanced E1a expression in tumor cells.
2Productivity
If E1a is expressed in both normal and tumor cells, then viral replication occurs in all cells, but tumor-selectivity is lost leading to non-selective toxicity
Solution Approach 1:
The patent applies local quality modification by creating cell-type-specific expression of E1a through selective deletion of Pea3 binding sites in the E1a promoter. The modified promoter maintains E1a expression in tumor cells (which have active Pea3) while reducing or eliminating expression in normal cells (which have inactive or different Pea3 expression patterns), thereby achieving local quality differentiation in viral protein expression.
3Reliability
If Pea3 binding sites are deleted from E1a regulatory sequence, then tumor-selective expression is achieved, but viral replication in normal cells is attenuated
Solution Approach 1:
The patent converts the potential harm of reduced viral replication in normal cells into a benefit by using the same Pea3 binding site deletion that restricts normal cell replication to simultaneously enable tumor-selective replication. The attenuation of viral replication in normal cells is transformed into a protective mechanism that prevents off-target toxicity while maintaining therapeutic efficacy in tumors.
4Reliability
If E1a expression is restricted to tumor cells only, then tumor-selectivity is improved, but viral replication potency in tumor cells may be reduced
Solution Approach 1:
The patent optimizes the balance between tumor-selectivity and replication potency by precisely modifying the E1a promoter parameters - specifically deleting Pea3 binding sites II and III while retaining other regulatory elements. This parameter modification ensures sufficient E1a expression in tumor cells for high replication potency while simultaneously achieving tumor-selectivity through reduced expression in normal cells.
Data Source
AI summary
Modified E1a regulatory sequences are provided, wherein at least one Pea3 binding site, or a functional portion thereof, is deleted. Also provided are modified E1a sequences that selectively express particular isoforms. Also provided is an E1b-19K clone insertion site. These modified sequences can be used individually, or in combination with one another, to provide tumor-selective expression of proteins.